This site is intended for healthcare professionals
News

FDA approves Prevnar 20 a pneumococcal 20 valent conjugate vaccine for adults aged 18 years and older.- Pfizer.

Read time: 1 mins
Last updated:9th Jun 2021
Published:10th Jun 2021
Pfizer Inc. announced that the FDA has approved Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older.
Condition: Infectious Diseases/Streptococcus
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest